Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RGNX Regenxbio

Trading 02-09 15:21:28 EST

10.33

+0.00

0.00%

High10.62	Low10.01	Vol440.37K
Open10.14	D1 Closing10.33	Amplitude5.91%
Mkt Cap522.94M	Tradable Cap427.90M	Total Shares50.62M
T/O4.54M	T/O Rate1.06%	Tradable Shares41.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RGNX","market":"US","secType":"STK","nameCN":"Regenxbio","latestPrice":10.33,"timestamp":1770668476437,"preClose":10.33,"halted":0,"volume":440370,"delay":0,"changeRate":0,"floatShares":41423137,"shares":50623086,"eps":-3.46438,"marketStatus":"Trading","change":0,"latestTime":"02-09 15:21:28 EST","open":10.14,"high":10.62,"low":10.01,"amount":4540674.446280001,"amplitude":0.059051,"askPrice":10.34,"askSize":490,"bidPrice":10.31,"bidSize":491,"shortable":3,"etf":0,"ttmEps":-3.46438,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770670800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1442462400000,"exchange":"NASDAQ","adjPreClose":10.33,"preHourTrading":{"tag":"盘前","latestPrice":10.37,"preClose":10.33,"latestTime":"09:20 EST","volume":8671,"amount":90964.668938,"timestamp":1770646818256,"change":0.04,"changeRate":0.003872,"amplitude":0.058083},"postHourTrading":{"tag":"盘后","latestPrice":10.49,"preClose":10.33,"latestTime":"19:05 EST","volume":119184,"amount":1231106.1829,"timestamp":1770422717776,"change":0.16,"changeRate":0.015489,"amplitude":0.028074},"volumeRatio":0.5746,"impliedVol":0.996,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/RGNX/wiki","defaultTab":"wiki","newsList":[{"id":"2607877110","title":"REGENXBIO Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2607877110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607877110?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:08","pubTimestamp":1769692080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RGNX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 08:08 ET (13:08 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RGNX","BK4505","BK4563"],"gpt_icon":0},{"id":"2607721713","title":"Nippon Shinyaku Partners with REGENXBIO for Exclusive Rights to RGX-111 and RGX-121","url":"https://stock-news.laohu8.com/highlight/detail?id=2607721713","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607721713?lang=en_us&edition=fundamental","pubTime":"2026-01-29 07:46","pubTimestamp":1769643988,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nippon Shinyaku Co. Ltd. published the original content used to generate this news brief on January 29, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL2fP15b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4563","BK4505","RGNX"],"gpt_icon":0},{"id":"2607774966","title":"FDA Clinical Hold Knocks REGENXBIO Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2607774966","media":"Benzinga_recent_news","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607774966?lang=en_us&edition=fundamental","pubTime":"2026-01-29 01:31","pubTimestamp":1769621460,"startTime":"0","endTime":"0","summary":"REGENXBIO shares sink after the FDA places a clinical hold on two gene therapy trials following a safety concern tied to abnormal tissue growth in one patient.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/28/REGENXBIO-Inc.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/28/REGENXBIO-Inc.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/01/50199815/fda-clinical-hold-knocks-regenxbio-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/01/50199815/fda-clinical-hold-knocks-regenxbio-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4563","BK4505","SMA","BK4217","BK4139","RGNX"],"gpt_icon":0},{"id":"2606122327","title":"BUZZ-U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker International","url":"https://stock-news.laohu8.com/highlight/detail?id=2606122327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606122327?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:12","pubTimestamp":1769609521,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Archer-Daniels-Midland, Danaher, Brinker InternationalEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL6N3YT0MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY","GKOS","LU1489326972.SGD","TXN","BROS","OTIS","STEL","GILD","EXTR","VFC","ABBV","QRVO","BK4535","NXT","LU1074936037.SGD","T","DHR","EAT","LU0795875169.SGD","PPG","SBUX","VEON","LU0823431563.USD","TXT","LU1291159041.SGD","LU0314106906.USD","MRK","SARO","LU0211327993.USD","KYIV","FFIV","LU1551013425.SGD","AU","NEM","ELV","LU2430703095.HKD","ADM","IE0009355771.USD","CDE","WIX","LU0320765489.SGD","LU0985481810.HKD","GEV","RGNX","CALC","IE00B894F039.SGD","HL","AI","LU2430703178.SGD"],"gpt_icon":1},{"id":"2606712122","title":"Regenxbio Shares Plunge on FDA Pausing Two Drug Development Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2606712122","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606712122?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:08","pubTimestamp":1769609280,"startTime":"0","endTime":"0","summary":"Shares of Regenxbio plunged after the Food and Drug Administration placed clinical holds on two drug development programs after a five-year-old participant in one study developed an intraventricular CNS tumor.The stock fell 33% to $9.02 in pre-market trading Wednesday after closing Tuesday at $13.41. At close, the stock was up 76% over the past 12 months.Regenxbio said Wednesday that the FDA's decision followed preliminary analysis of the tumor, which was observed in a participant in the company's phase 1/2 study of RGX-111 to treat Hurler syndrome, a genetic disease.President and Chief Executive Officer Curran Simpson said the company was surprised by the FDA's decision to pause the RGX-121 program.\"These are separate therapies, and the positive safety profile of RGX-121 in more than 30 patients treated, including those dosed nearly seven years ago, remains unchanged,\" Simpson said. \"Patient safety is our top priority, and we, our investigators, and the patient community remain confid","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"Regenxbio Shares Plunge on FDA Pausing Two Drug Development Programs","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","RGNX","BK4505","BK4139"],"gpt_icon":0},{"id":"2606714456","title":"Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Fed Policy Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2606714456","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606714456?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:49","pubTimestamp":1769608173,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively traded Invesco QQQ Trust (QQQ) was 0.8% higher in Wednesday's premarket activity, ahead of the Federal O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBB","XLI","XLF","BETH","US7Y.BOND","IYK","XLY","FAS","IYH","US2Y.BOND","XLP","US10Y.BOND","BITO","SOXX","VHT.AU","US6M.BOND","RGNX","US30Y.BOND","XSD","RTH","XLK","SPY","US3Y.BOND","VIS","IYE","XLE","ASML","UNG","EETH","IYW","US5Y.BOND","US12M.BOND","PB","FAZ","OTIS","RTH.AU","EQR","USO","XLV","VDC","VHT","XRT","STEL","IGM","IYJ","EDU.AU"],"gpt_icon":1},{"id":"2606719765","title":"Regenxbio Says RGX-111, RGX-121 Placed on Clinical Hold by FDA; Shares Tumble Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2606719765","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606719765?lang=en_us&edition=fundamental","pubTime":"2026-01-28 21:00","pubTimestamp":1769605216,"startTime":"0","endTime":"0","summary":"Regenxbio  said Wednesday that the US Food and Drug Administration has placed a clinical hold on its investigational gene therapies RGX-111 and RGX-121 for potential treatment of Hurler syndrome and Hunter syndrome, respectively.The company said the FDA's decision regarding RGX-111 was made after a preliminary analysis of a case of neoplasm in an asymptomatic participant treated with RGX-111 four years earlier in a phase 1/2 study. An investigation to determine whether the case is drug-related is being conducted, Regenxbio said, adding that causality has not been established.The FDA's hold on RGX-121 is due to similarities in products, study populations, and shared risk between its clinical studies with RGX-111, the company said.Regenxbio Chief Executive Curran Simpson said the clinical hold on RGX-121 came as a surprise because RGX-111 and RGX-121 are separate therapies, and RGX-121 has a positive safety profile.Shares of Regenxbio were down more than 30% in recent premarket activity ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","RGNX","BK4563","BK4139"],"gpt_icon":0},{"id":"2606716700","title":"Regenxbio announces FDA places clinical hold on RGX-111","url":"https://stock-news.laohu8.com/highlight/detail?id=2606716700","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606716700?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:41","pubTimestamp":1769604103,"startTime":"0","endTime":"0","summary":"Regenxbio (RGNX) announced that the U.S. FDA placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-announces-fda-places-clinical-hold-on-rgx-111-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-announces-fda-places-clinical-hold-on-rgx-111-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","RGNX","BK4505","BK4139"],"gpt_icon":0},{"id":"2606716091","title":"Regenxbio down 35% to $8.59 after FDA places clinical hold on RGX-111","url":"https://stock-news.laohu8.com/highlight/detail?id=2606716091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606716091?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:41","pubTimestamp":1769604089,"startTime":"0","endTime":"0","summary":"07:37 EST Regenxbio (RGNX) down 35% to $8.59 after FDA places clinical hold on RGX-111 Published first on TheFly – the ultimate source for real-tim...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-down-35-to-8-59-after-fda-places-clinical-hold-on-rgx-111-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-down-35-to-8-59-after-fda-places-clinical-hold-on-rgx-111-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","BK4505","BK4139","RGNX"],"gpt_icon":0},{"id":"2606716061","title":"Regenxbio Shares Slide 32% Premarket After U.S. FDA Places Clinical Hold on Co's Gene Therapy Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2606716061","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606716061?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:41","pubTimestamp":1769604086,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL4N3YT1EP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RGNX","BK4139","BK4505","BK4563"],"gpt_icon":0},{"id":"2606914716","title":"Regenxbio Inc - FDA Places Clinical Hold on Rgx-121 for Mps Ii","url":"https://stock-news.laohu8.com/highlight/detail?id=2606914716","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606914716?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:30","pubTimestamp":1769603448,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT0KC:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","BK4505","RGNX"],"gpt_icon":0},{"id":"2606716143","title":"Regenxbio Inc: Has Not yet Received Full Clinical Hold Letter and Awaits Additional Details From FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2606716143","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606716143?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:30","pubTimestamp":1769603448,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT0KC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","RGNX","BK4563"],"gpt_icon":0},{"id":"2606716112","title":"Regenxbio Inc - No Neoplasm Evidence in Other Rgx-111 or Rgx-121 Participants","url":"https://stock-news.laohu8.com/highlight/detail?id=2606716112","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606716112?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:30","pubTimestamp":1769603448,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YT0KC:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","BK4505","RGNX"],"gpt_icon":0},{"id":"2606136716","title":"FDA Halts Regenxbio Gene Therapy Trials After Tumor Case","url":"https://stock-news.laohu8.com/highlight/detail?id=2606136716","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606136716?lang=en_us&edition=fundamental","pubTime":"2026-01-28 20:30","pubTimestamp":1769603442,"startTime":"0","endTime":"0","summary":"Regenxbio Inc. is facing a regulatory setback after the U.S. Food and Drug Administration  placed clinical holds on its investigational gene therapies RGX-111 and RGX-121, which target the ultra-rare conditions MPS I  and MPS II , respectively. The action follows the preliminary discovery of a neoplasm in a participant who received RGX-111, with genetic analysis revealing an AAV vector genome integration linked to proto-oncogene overexpression. While the investigation into the drug's role in this event is ongoing and causality has not been established, the FDA extended the hold to RGX-121 due to similarities in the therapies and patient populations. Regenxbio has not yet received the full clinical hold letter and is awaiting further details from the FDA.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL6G0Ct5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4505","BK4139","BK4563"],"gpt_icon":0},{"id":"2602756882","title":"Regenxbio highlights progress, anticipated milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602756882","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602756882?lang=en_us&edition=fundamental","pubTime":"2026-01-12 04:55","pubTimestamp":1768164912,"startTime":"0","endTime":"0","summary":"REGENXBIO (RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenxbio-highlights-progress-anticipated-milestones-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenxbio-highlights-progress-anticipated-milestones-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","RGNX","BK4563","BK4139"],"gpt_icon":0},{"id":"2602504755","title":"BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2602504755","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602504755?lang=en_us&edition=fundamental","pubTime":"2026-01-12 04:01","pubTimestamp":1768161707,"startTime":"0","endTime":"0","summary":"BRIEF-Regenxbio Highlights Key 2026 Catalysts And Announces Positive Long-Term Functional Outcomes In Lead Duchenne Gene Therapy ProgramJan 11 (Reuters) - Regenxbio Inc RGNX.O:REGENXBIO HIGHLIGHTS KEY","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA1MGFYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0203345920.USD","IE00B19Z3B42.SGD","LU2087621335.USD","SG9999015978.USD","LU0661504455.SGD","LU2023251221.USD","LU0965509101.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0949170772.SGD","BK4588","LU0689472784.USD","IE0002141913.USD","LU1732800096.USD","LU0965509010.AUD","IE00B4R5TH58.HKD","LU1023059063.AUD","LU1244550494.USD","LU0114720955.EUR","BK4550","BK4566","LU0689626769.HKD","IE0009355771.USD","ABBV","LU0320765646.SGD","IE00BVYPNV92.GBP","LU0122379950.USD","RGNX","LU0820561909.HKD","LU2133065610.SGD","LU0708994859.HKD","IE00BFTCPJ56.SGD","SG9999015945.SGD","LU1074936037.SGD","LU1267930573.SGD","LU2089284900.SGD","IE00BLSP4239.USD","BK4533","IE00BJT1NW94.SGD","BK4581","LU0985320562.USD","LU2129689514.USD","IE00BDGV0183.EUR","IE00B19Z3581.USD","LU2089283258.USD","IE00B3PB1722.GBP","LU1934455194.USD","LU2129689431.USD","IE00BBT3K403.USD","LU0158827948.USD"],"gpt_icon":0},{"id":"2602550476","title":"Regenxbio Reports Positive Long-Term Results in Duchenne Gene Therapy and Plans 2026 BLA Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2602550476","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602550476?lang=en_us&edition=fundamental","pubTime":"2026-01-12 04:00","pubTimestamp":1768161629,"startTime":"0","endTime":"0","summary":"Regenxbio Inc. has announced new long-term functional data from its Phase I/II clinical trial of RGX-202, a gene therapy for Duchenne Muscular Dystrophy. The data demonstrate a durable treatment effect at 18 months at the pivotal dose. The company continues robust patient enrollment in a confirmatory trial and expects the majority of patients to be dosed by the planned Biologics License Application  filing in mid-2026. Regenxbio also anticipates sharing pivotal topline data in early Q2 2026 and plans to submit the BLA under the accelerated approval pathway in mid-2026. Results were highlighted in a presentation at the 44th Annual J.P. Morgan Healthcare Conference, with a webcast available on the company’s website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, inv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDLbZwZr7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RGNX","BK4139","BK4563","BK4505"],"gpt_icon":0},{"id":"2602550473","title":"Regenxbio Inc - Expects Pivotal Trial Data in Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602550473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602550473?lang=en_us&edition=fundamental","pubTime":"2026-01-12 04:00","pubTimestamp":1768161602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA1MGFYP:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","BK4139","RGNX","BK4563"],"gpt_icon":0},{"id":"2602550429","title":"Regenxbio Inc - to Receive $100 Mln Payment From Abbvie in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602550429","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602550429?lang=en_us&edition=fundamental","pubTime":"2026-01-12 04:00","pubTimestamp":1768161602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA1MGFYP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2129689605.HKD","LU0098860793.USD","IE00BVYPNW00.USD","LU2112291526.USD","LU2237443895.HKD","LU0965509101.SGD","LU0029864427.USD","RGNX","SG9999015986.USD","IE00BSNM7G36.USD","LU1162221912.USD","LU1551013425.SGD","BK4563","BK4581","LU0965509010.AUD","LU2129689431.USD","IE00BDGV0183.EUR","LU1093756325.SGD","LU1929549753.HKD","SG9999011175.SGD","LU0912757837.SGD","LU2129689514.USD","LU0861579265.USD","IE00BBT3K403.USD","LU1732799900.SGD","LU1244550577.SGD","LU0289739699.SGD","IE00B19Z3581.USD","BK4566","LU0689626769.HKD","LU2089284900.SGD","LU0058720904.USD","BK4559","LU2237443622.USD","LU1430594728.SGD","LU2237443465.HKD","LU1496350502.SGD","BK4585","LU1983299246.USD","LU1291159041.SGD","LU0256863811.USD","BK4550","IE00B19Z3B42.SGD","LU1267930573.SGD","LU2089984988.USD","LU1244550221.USD","LU0456855351.SGD","ABBV","LU2347655156.SGD","IE0002270589.USD"],"gpt_icon":0},{"id":"2602455042","title":"Regenxbio Inc - New Rgx-202 Data Shows Long-Term Effect at 18 Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2602455042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602455042?lang=en_us&edition=fundamental","pubTime":"2026-01-12 04:00","pubTimestamp":1768161602,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUA1MGFYP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4563","BK4505","RGNX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.regenxbio.com","stockEarnings":[{"period":"1week","weight":-0.0744},{"period":"1month","weight":-0.3222},{"period":"3month","weight":-0.0785},{"period":"6month","weight":0.3159},{"period":"1year","weight":0.2254},{"period":"ytd","weight":-0.2826}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0015},{"period":"3month","weight":0.0293},{"period":"6month","weight":0.0839},{"period":"1year","weight":0.139},{"period":"ytd","weight":0.0128}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":-0.091067},{"month":2,"riseRate":0.272727,"avgChangeRate":0.011009},{"month":3,"riseRate":0.6,"avgChangeRate":0.015225},{"month":4,"riseRate":0.6,"avgChangeRate":0.035795},{"month":5,"riseRate":0.3,"avgChangeRate":-0.022478},{"month":6,"riseRate":0.6,"avgChangeRate":0.047674},{"month":7,"riseRate":0.4,"avgChangeRate":-0.001741},{"month":8,"riseRate":0.4,"avgChangeRate":0.017624},{"month":9,"riseRate":0.6,"avgChangeRate":0.07131},{"month":10,"riseRate":0.363636,"avgChangeRate":-0.060741},{"month":11,"riseRate":0.727273,"avgChangeRate":0.164969},{"month":12,"riseRate":0.363636,"avgChangeRate":-0.05132}],"exchange":"NASDAQ","name":"Regenxbio","nameEN":"Regenxbio"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Regenxbio,RGNX,Regenxbio股票,Regenxbio股票老虎,Regenxbio股票老虎国际,Regenxbio行情,Regenxbio股票行情,Regenxbio股价,Regenxbio股市,Regenxbio股票价格,Regenxbio股票交易,Regenxbio股票购买,Regenxbio股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Regenxbio(RGNX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Regenxbio(RGNX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}